The Department of Health and Human Services is laying the necessary groundwork for the distribution of a safe and effective COVID-19 vaccine by ensuring that all tribal health programs and urban Indian organizations have the choice on how they receive the COVID-19 vaccine. Today, HHS is announcing that all tribal health programs and UIOs have ...
On the occasion of the 32nd annual World AIDS Day, December 1, 2020, HHS Secretary Alex Azar issued the following statement: “Even as COVID-19 has exacerbated so many health challenges, the Trump Administration remains deeply committed to the global fight against HIV/AIDS and our goal of ending the HIV epidemic in America by 2030. This ...
CaringWays Partners with Clearwater to Develop Best-in-Class Cyber Risk Management and HIPAA Compliance Program Business Wire Powered by WPeMatico
17 HIPAA settlements in 2020 Becker’s Hospital Review Powered by WPeMatico
Aurora announces HIPAA Compliance PRWire Powered by WPeMatico
5 lessons learned from HIPAA ‘Right of Access’ fines this year Modern Healthcare Powered by WPeMatico
Today, the Department of Health and Human Services (HHS) through a Notice published in the Federal Register announced a policy to enhance transparency at HHS by requiring that all assumptions, working papers, models, and other information used as part of any impact analysis associated with a rule or demonstration project are shared at the time ...
COVID-19 Has Not Slowed Down HIPAA Enforcement | Chiesa Shahinian & Giantomasi PC JD Supra Powered by WPeMatico
The U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DOD) have jointly awarded an $11.6 million contract to Puritan Medical Products Company, LLC, to expand domestic production capacity of Cue Sample Wands, the nasal swabs used exclusively with the COVID-19 cartridge-based molecular testing system developed and manufactured by Cue ...
The U.S. Department of Health and Human Services today announced plans to allocate initial doses of Regeneron’s investigational monoclonal antibody therapeutic, casirivimab and imdevimab, which received emergency use authorization from the U.S. Food and Drug Administration on November 21, 2020, for treatment of non-hospitalized patients with mild or moderate confirmed cases of COVID-19 at high ...
